Despite the pandemic’s impact, the volume of healthcare private equity transactions accelerated in the latter half of 2020. Now in a new year with a new administration, investors should expect both new opportunities and challenges to emerge in the healthcare sector. To help navigate the evolving landscape, McDermott Will & Emery is dedicating a series of podcast episodes to healthcare private equity. In this first installment, McDermott Partner Krist Werling talks with Brian Fortune, Senior Director at Farragut Square Group, about the top priorities private equity investors should focus on under the Biden administration.

Peloton Equity, LLC (“Peloton”), a healthcare-focused private equity firm, has closed its second fund Peloton Equity II, L.P. (“Fund II”) with $152.25 million in limited partner and general partner commitments. Fund II will seek to continue Peloton’s strategy of investing growth capital in innovative healthcare companies and partnering with management teams to achieve accelerated growth and value creation. Peloton invests across a wide range of healthcare sectors with a focus on differentiated companies that it believes are positioned to benefit from secular industry tailwinds.

The healthcare sector is drawing interest from private equity investors this year, with seven deals announced since Jan. 25, according to this list compiled by Becker’s Hospital CFO Report.

This Diagnosing Health Care episode dives into the growth of physician practices accepting risk-based payments from health plans and examines why these practices are attractive to investors. Special guest Jason Madden, Managing Director at Accordion, and Epstein Becker Green attorneys Joshua Freemire, Jason Christ, and Tim Murphy, discuss the health regulatory considerations investors must assess when evaluating investment opportunities with physician practices accepting risk-based payments.